Company Overview and News

 
Anteo Diagnostics surges on lithium-ion leverage

2017-12-19 proactiveinvestors.com.au
Anteo Diagnostics Ltd (ASX:ADO) surged 64% to $0.023 late morning on news of a development project for its AnteoCoat nano-coating technology for lithium-ion batteries.

 
Anteo Diagnostics leads the ASX % Gainers on leverage to lithium-ion battery market

2017-10-18 proactiveinvestors.com.au
Anteo Diagnostics Ltd (ASX:ADO) shares have soared 111% by midday on heavy volume of 49 million shares.

 
BioVendor Acquires 100% Of The Shares Of DIAsource ImmunoAssays SA

2017-10-11 devicespace
BioVendor - Laboratorní medicína a.s. (BioVendor) acquired 100% of the shares of DIAsource ImmunoAssays SA from the Australian stock listed company, Anteo Diagnostics (ASX: ADO). Anteo Diagnostics had acquired DIAsource in January 2016.

 
BioVendor Acquires 100% of the Shares of DIAsource ImmunoAssays SA

2017-10-10 prnewswire
BioVendor - Laboratorní medicína a.s. (BioVendor) acquired 100% of the shares of DIAsource ImmunoAssays SA from the Australian stock listed company, Anteo Diagnostics (ASX: ADO). Anteo Diagnostics had acquired DIAsource in January 2016.

 
BioVendor adquiere el 100% de las acciones de DIAsource ImmunoAssays SA

2017-10-10 prnewswire
BioVendor - Laboratorní medicína a.s. (BioVendor) adquirió el 100% de las acciones de DIAsource ImmunoAssays SA de la compañía Anteo Diagnostics (ASX: ADO). Anteo Diagnostics había adquirido DIAsource en enero del 2016.

 
BioVendor erwirbt 100% der Anteile an DIAsource ImmunoAssays SA

2017-10-10 prnewswire
Mit Wirkung zum September 2017, erwarb das tschechische Unternehmen BioVendor - Laboratorní medicína a.s. (BioVendor) 100% der Anteile an der DIAsource ImmunoAssays SA von der australischen Aktiengesellschaft Anteo Diagnostics (ASX: ADO). Anteo Diagnostics hatte im Januar 2016 DIAsource erworben.

 
Společnost BioVendor získá 100% akcií společnosti DIAsource ImmunoAssays SA

2017-10-10 prnewswire
BioVendor - Laboratorní medicína a.s. (BioVendor) získala 100% akcií společnosti DIAsource ImmunoAssays SA od australské akciové společnosti Anteo Diagnostics (ASX: ADO). Společnost Anteo Diagnostics získala DIAsource v lednu 2016.

 
BioVendor - Laboratorní medicína a.s. (BioVendor) a acquis 100% des actions de DIAsource ImmunoAssays SA

2017-10-10 prnewswire
BioVendor - Laboratorní medicína a.s. (BioVendor) a acquis 100% des actions de DIAsource ImmunoAssays SA détenues depuis janvier 2016 par la société australienne cotée en bourse Anteo Diagnostics (ASX: ADO). DIAsource ImmunoAssays est une société belge spécialisée depuis 30 ans dans le développement, la fabrication, la vente et la distribution de tests de diagnostics sanguins et de solutions d'instrumentation ouvertes dans le diagnostic médical clinique.

 
DIAsource ImmunoAssays SA hat die Viro-Immun Diagnostics GmbH übernommen

2017-09-14 prnewswire
Mit Wirkung zum September 2017, erwarb das belgische Unternehmen DIAsource ImmunoAssays SA - ein Spezialist in der Entwicklung, dem Verkauf und Vertrieb von Produkten der klinischen Diagnostik - die Vermögenswerte der Viro-Immun Diagnostics GmbH.

 
DIAsource ImmunoAssays - adquisición de todos los activos de Viro-Immun Diagnostics GmbH

2017-09-14 prnewswire
Desde septiembre de 2017, DIAsource ImmunoAssays SA, empresa con sede en Bélgica y especializada en el desarrollo, la venta y la distribución de productos de diagnóstico clínico, adquirió los activos de Viro-Immun Diagnostics GmbH, empresa alemana especializada desde hace 30 años en el desarrollo y fabricación de kits de diagnósticos de laboratorio para el diagnóstico médico de enfermedades infecciosas y autoinmunes.

 
Cardinal Resources, 88 Energy, Fastbrick Robotics, Slater & Gordon among the early movers

2017-07-13 proactiveinvestors.com.au
The ASX 200 (XJO) rebounded early on, tracking Wall Street, which was heartened by dovish comments by US Federal Reserve chair, Janet Yellen in testimony to Congress.

 
Anteo Diagnostics to receive grant for unique vitamin D assay

2017-01-27 proactiveinvestors.com.au
Anteo Diagnostics’ (ASX:ADO) subsidiary DIAsource Immunoassays SA will receive a grant of €1.4 million to develop a unique vitamin D assay for the in vitro diagnostic (IVD) market.

 
Anteo Diagnostics meets vendor finance commitment related to DIAsource acquisition

2017-01-17 proactiveinvestors.com.au
Peter Harding-Smith, Anteo Group CFO, commented: "We continue to be very satisfied with the performance of DIAsource and look forward to providing an update on the 2016 financial performance of DIAsource in the near future."

 
Anteo Diagnostics trades higher as it strengthens intellectual property

2017-01-12 proactiveinvestors.com.au
Recent development work in the application of this technology in the medical device arena discovered a number of new application areas, leading Anteo to establishing a stronger intellectual property position.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...